Shots:

•  Study involves assessing of inhaled TLR9 agonist with anti-PD-1 in mouse preclinical model- leading a long term survival in two different mouse lung tumour models 
• Administration of SD-101 in lungs of mice with metastatic tumours results in ~90% reduction in tumour burden in lung and liver both enhancing survival time and survival rate of 90-100 days
• An unpublished P-1b study involving TLR9 agonist- DV281 for lung tumours and lung metastases has shown corresponding results in above models of inhaled DV281 being evaluated for advanced NSLC patients 

Ref: Dynavax | Image: Market Exclusive